Inhibitor Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Inhibitor Therapeutics, Inc. (INTI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$3.03 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-03-29
- Inhibitor Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$1.17M, a 109.47% decline year-over-year.
- Inhibitor Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was -$664.76K.
- Inhibitor Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was -$654.52K.
- Inhibitor Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-03-31 was -$539.60K.
- Inhibitor Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$3.03M, a 125.39% decline from fiscal 2022.
- Inhibitor Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was $11.92M.
- Inhibitor Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$498.63K.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$1.83M derived: sum of 2 quarters · filed 2024-03-29 | -$2.49M derived: sum of 3 quarters · filed 2024-03-29 | -$3.03M 10-K · filed 2024-03-29 |
| 2023-09-30 | -$664.76K 10-Q · filed 2023-11-13 | -$1.32M derived: sum of 2 quarters · filed 2023-11-13 | -$1.86M 10-Q · filed 2023-11-13 | $10.46M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | -$654.52K 10-Q · filed 2023-08-11 | -$1.19M 10-Q · filed 2023-08-11 | $11.13M derived: sum of 3 quarters · filed 2024-03-29 | $11.00M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | -$539.60K 10-Q · filed 2023-05-15 | $11.78M derived: sum of 2 quarters · filed 2024-03-29 | $11.65M derived: sum of 3 quarters · filed 2024-03-29 | $11.53M derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $12.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $12.19M derived: sum of 2 quarters · filed 2024-03-29 | $12.07M derived: sum of 3 quarters · filed 2024-03-29 | $11.92M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$128.10K 10-Q · filed 2023-11-13 | -$255.53K derived: sum of 2 quarters · filed 2023-11-13 | -$403.76K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$127.43K 10-Q · filed 2023-08-11 | -$275.65K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$148.22K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$498.63K 10-K · filed 2023-03-31 |